M
MGRX
vs
S&P 500
S&P 500
Over the past 12 months, MGRX has underperformed S&P 500, delivering a return of -88% compared to the S&P 500's +13% growth.
Stocks Performance
MGRX vs S&P 500
Performance Gap
MGRX vs S&P 500
Performance By Year
MGRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mangoceuticals Inc
Glance View
Mangoceuticals, Inc. engages in developing, marketing, and selling men’s wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The firm has developed and is in the process of preparing to commercially market a brand of erectile dysfunction (ED) product under the brand name Mango. The Company’s Mango ED product includes the ingredients, such as Tadalafil (10 milligrams (mg)), Oxytocin (100 International units (IU)) and L-Arginine (50mg), and Tadalafil (20mg), Oxytocin (100IU) and L-Arginine (50mg). The firm connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com for the provision of care via telehealth through its customer portal and provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including its Mango ED product.
